Abstract Infection of humans and chimpanzees with Hepatitis C virus (HCV) results in either the resolution of the acute infection or its progression to a persistent infection associated with chronic liver disease. In cohorts of human patients, resolution of HCV infection has been associated with homozygosity for both C1 + HLA-C and its cognate inhibitory receptor, KIR2DL3. Compared here are the killer cell immunoglobulinlike receptors (KIR) and major histocompatibility complex (MHC) class I factors of chimpanzees who resolve, or resist, HCV infection with those chimpanzees who progress to chronic infection. Analysis of Pt-KIR gene content diversity associated two of the 12 Pt-KIR with clinical outcome. Activating Pt-KIR3DS2 and inhibitory Pt-KIR2DL9 are strong receptors specific for the C2 epitope. They are encoded by neighboring genes within the Pt-KIR locus that are in strong linkage disequilibrium. HCV-infected chimpanzees with KIR genotypes containing Pt-KIR3DS2 and KIR2DL9 are significantly more likely to progress to chronic infection than infected chimpanzees lacking the genes (p=0.0123 and p=0.0045, respectively), whereas human HLA-B allotypes having the C1 epitope are unusual, such allotypes comprise about one quarter of the chimpanzee Patr-B allotypes. Homozygous C1-+ Patr-B are enriched in chimpanzees with chronic HCV infection, and the compound genotype of homozygous C1 + Patr-B combined with either Pt-KIR3DS2 or Pt-KIR2DL9 is more strongly associated with disease progression than either factor alone (p=0.0031 and p=0.0013, respectively). Thus, despite similarities suggesting a common basis in disease resistance, there are substantial differences in the KIR and MHC class I correlations observed for HCV-infected humans and chimpanzees, consistent with the divergence of their KIR and MHC class I systems.
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Keywords MHC . KIR . Hepatitis C virus . Chronic infection . Chimpanzee Natural killer (NK) cells are vital lymphocytes that contribute to innate immunity and adaptive immunity and also to reproduction during formation of the placenta (Parham and Moffett 2013) . In the immune system, NK cells are prominent in providing defense against viral infections (Lanier 2008) . The education of NK cells, which teaches them to identify and kill virus-infected cells, is dependent upon NK cell receptors that recognize polymorphic determinants of MHC class I molecules (Watzl 2014) . In humans, the diverse family of killer cell immunoglobulin-like receptors (KIR) provides NK cell receptors that recognize polymorphic determinants of HLA-A, -B, and -C molecules (Parham and Moffett 2013) . Of particular importance are the inhibitory and activating KIR2D that recognize the C1 and C2 epitopes of HLA-C. These epitopes are determined by dimorphism at position 80 in the α 1 domain, where asparagine and lysine specify the C1 and C2 epitopes, respectively (Colonna et al. 1993) . The KIR2DL2/3 gene that encodes inhibitory C1 receptors is polymorphic and comprises two distinct lineages of alleles called KIR2DL2 and KIR2DL3. In an epidemiological study of hepatitis C virus (HCV) infection, Khakoo et al. showed that resolution of acute HCV infection was associated with homozygosity for KIR2DL3 and C1-bearing HLA-C in cohorts of Europeans and African-Americans (Khakoo et al. 2004) . Corroborating this finding is the observed association between C2 epitope homozygosity and the failure to respond to HCV treatment (Suppiah et al. 2011) .
The chimpanzee is the only good animal model for human HCV infection. In both humans and chimpanzees, some infected individuals are able to resolve the acute infection, while others develop a chronic infection that can lead to severe liver disease. A majority of humans infected with HCV (∼75-85 %) become chronically infected (http://www.cdc.gov), whereas it is a minority (∼30 %) of chimpanzees that develop chronic infections (Bettauer 2010 ). The chimpanzee is also the species for which the genetics and immunogenetics are most like their human counterparts (Adams and Parham 2001; Prado-Martinez et al. 2013 ). The chimpanzee (Pan troglodytes) has strict Patr-A, -B, and -C orthologs of human HLA-A, -B, and -C, and has both the C1 and C2 epitopes that are recognized by activating and inhibitory KIR (Adams and Parham 2001; Moesta et al. 2009) . One difference between the two species is that a significant proportion of the allotypes of Patr-B, the chimpanzee ortholog of HLA-B, has the C1 epitope and is recognized by C1-specific KIR. Only two HLA-B allotypes have the C1 epitope: HLA-B*73:01 is rare and HLA-B*46 is restricted to Southeastern Asian populations (Abi-Rached et al. 2010) . In contrast to MHC class I, the human and chimpanzee KIR (Pt-KIR) recognizing MHC-C are not strict orthologs but form part of the same lineage of KIR, called lineage III (Khakoo et al. 2000) . Distinguishing the chimpanzee KIR locus is a greater diversity of C1-specific and C2-specific receptors; distinguishing the human KIR locus is the two distinctive A and B forms of KIR haplotype that appear subject to different selective pressure (Abi-Rached et al. 2010) .
In defining the structure and variability of the chimpanzee KIR gene family, we studied a panel of 39 chimpanzees comprising 35 western chimpanzees (Pan troglodytes verus), two eastern chimpanzees (Pan troglodytes schweinfurthii), one central chimpanzee (Pan troglodytes troglodytes), and one individual for whom the subspecies is unknown (Abi-Rached et al. 2010) . That 24 of the individuals in this panel had been subjects for experimental HCV infection and vaccination studies (Cooper et al. 1999 ) enabled us to explore the influence of KIR and MHC class I type on the outcome of HCV infection.
Major features of KIR diversity are that haplotypes differ in both number and type of genes they contain. This is clearly seen in Fig. 1 , which compares the presence and absence of 12 Pt-KIR genes in the cohort of 24 chimpanzees. These genes include eight that encode MHC-C receptors: three C1 receptors (activating Pt-KIR3DS6 and inhibitory Pt-KIR2DL6 and Pt-KIR2DL8) and five C2 receptors (activating Pt-KIR3DS2, and inhibitory Pt-KIR2DL9, Pt-KIR3DL5, Pt-KIR3DL4, and Pt-KIR2DL7). The other four genes encode Pt-KIR3DL3, Pt-KIR2DL4, and Pt-KIR2DL5, for which ligands are not established, and Pt-KD3L1/2 that recognizes MHC-A and MHC-B (Khakoo et al. 2000) . Two divergent Ba^and Bbâ llotypes of Pt-KIR3DL1/2 (formerly Pt-KIR3DL1/2 and Pt-KIR3DL3 in (Khakoo et al. 2000) ) are distinguished in Fig. 1 . The cohort of 24 chimpanzees divides into a first group of 11 chimpanzees that resisted HCV infection (Fig. 1, upper  part) and a second group of chimpanzees that failed to resist HCVand developed chronic infection (Fig. 1, lower part) . The first group consists of two individuals (LouLou B and Todd) who were not vaccinated and resolved acute HCV infection, four individuals who were vaccinated and became protected against subsequent challenge with the virus, and five vaccinated individuals who became infected on subsequent challenge with HCV and then resolved the infection. The second group, of 13 chimpanzees, developed chronic infection on viral challenge, seven of whom were vaccinated and six who were not (Cooper et al. 1999) . As is clearly seen in Fig. 1 , of the 12 chimpanzee KIR genes, Pt-KIR3DS2 and Pt-KIR2DL9 are more highly represented in the group with chronic disease (10 of 13 individuals) than in the group who resisted HCV (two of 11 individuals). Absence of these two Pt-KIR genes correlates with resistance and resolution of HCV infection, with an odds ratio (OR) of 22.5 (p=0.0045) for Pt-KIR2DL9 and 15.0 (p=0.0123) for Pt-KIR3DS2 (Fig. 2) . None of the other KIR varies significantly between the groups of resistant and susceptible chimpanzees, as is exemplified by the OR of 0.8 for Pt-KIR3DL5 and the OR of 0.5 for Pt-KIR3DS6.
The order of the Pt-KIR genes in Fig. 1 reflects their order in the chimpanzee Pt-KIR locus (Abi-Rached et al. 2010). Thus, Pt-KIR3DS2 and Pt-KIR2DL9 are seen to be neighboring genes (Fig. 1) . Moreover, they are only 2 kbp apart because of the characteristically short and homologous intergenic sequences that separate KIR genes (Wilson et al. 2000) . As a consequence there is strong linkage disequilibrium (LD) between Pt-KIR3DS2 and Pt-KIR2DL9, as seen from only two of the 24 chimpanzees having one of these genes and not the other, as well as comparison of chimpanzee KIR haplotypes (Abi-Rached et al. 2010). Selection could also be having a role in maintaining the linkage between Pt-KIR3DS2 and Pt-KIR2DL9, which encode strong activating and inhibitory C2 receptors, respectively.
We compared the groups of resistant and susceptible chimpanzees for differences in the distribution of the C1 and C2 epitopes of MHC-C, but no significant differences were observed. However, an interesting trend was observed in the segregation of alleles encoding C1 + Patr-B allotypes. Indeed, that three individuals of the susceptible group are homozygous for C1 + Patr-B, compared to none of the resistant group suggested that homozygosity for C1-bearing Patr-B could be a risk factor for chronic infection and that its absence might favor resolution of infection. Consistent with this hypothesis, the compound genotype, defined by absence of both Pt-KIR2DL9 and homozygous C1 + Patr-B, was more strongly correlated with resolution of HCV infection (OR of 33.3; p=0.0013) than either factor alone. Similarly, the absence of Pt-KIR3DS2 combined with absence of homozygous C1 + Patr-B favored resolution of infection (OR of 24.8; p=0.0031).
The resolution of human HCV infection was correlated with homozygosity for C1-specific KIR2DL3 and for C1 + HLA-C (Khakoo et al. 2004) . In that analysis, heterozygosity for C1 + HLA-C, which is due to the C1 + HLA-C/ C2
+ HLA-C genotype, provided little improvement in Fig. 1 Absence of the C2-specific Pt-KIR2DL9 (inhibitory) and Pt-KIR3DS2 (activating) favors resolution of chimpanzee HCV infection. Shows Pt-KIR and MHC C1/C2 content in a panel of 24 chimpanzees infected with HCV. C1 and C2 contents are listed on the left side of the panel and include C1 contributed by C1 + Patr-B (allotypes with valine 76 and asparagine 80). Pt-KIR gene content is shown in the central part of the panel: lineage III Pt-KIR with known specificities for MHC class I are colored either blue (C1 specific) or pink (C2 specific), and specificity is given below their names; names of activating KIR are in green. Virus doses (expressed in 50 % chimpanzee infectious doses, CID 50 ) used for postvaccination challenge, vaccination status, and HCV infection outcome are listed on the right side of the panel and have been published; for Paula (#W176), Tibi (#L559) and Chatter (#L357) (Choo et al. 1994) and for the remaining individuals (Cooper et al. 1999) . The vaccination and challenge protocols have also been described previously (Choo et al. 1994; Cooper et al. 1999 ). The population and KIR typing methods are described in (Abi-Rached et al. 2010) . MHC-B and -C content was previously completely characterized (two alleles per locus) for 13 of the 24 individuals for Patr-C and for 18 of the 24 individuals for Patr-B (Cooper et al. 1999) . We investigated the C1/C2 content at the MHC-B and -C loci for the remaining individuals by amplification and sequencing of exon 2, which encodes the α1 domain, the domain that contains the C1 or C2 epitope (PCR primers and amplification conditions are available on request). This study was approved by the Stanford University administrative panels on human subjects in medical research and laboratory animal care B C1/C1 and 2DL9 B C1/C1 and 3DS2 Fig. 2 Statistical analyses of the correlations between chimpanzee MHC class I, KIR, and resistance to HCV infection. Shown are Pt-KIR 2DL9, 3DS2, 3DL5, 3DS6 and MHC-C C1, C2, C1/C1, C2/C2, MHC-B C1, C1/ C1, and BC1 or C2 only^frequencies for individuals with resolved and persistent HCV infection. An odds ratio (OR) larger than one indicates a protective association. For genetic factors in bold type, the lack of the factors was considered for the analysis. Only genetic factors having frequencies in the range (∼17-83 %), where significant difference was potentially detectable, were included in the analysis (one exception being MHC-B C1/C1, with a frequency of 12.5 %). Significance was assessed using a two-tailed Fisher Exact test. NS not significant, NA not available outcome, suggesting that absence of C2 could be an important factor for resolving HCV infection. Supporting this hypothesis is the association of C2 homozygosity with failure to respond to treatment for HCV (Suppiah et al. 2011) . In a C1 + HLA-C homozygote, but not a heterozygote, the strong inhibitory C2 receptor KIR2DL1 is rendered nonfunctional. Although accomplished by a different mechanism, a similar trend is seen in the chimpanzee model. Elimination of the strong C2 receptors, Pt-KIR3DS2 and Pt-KIR2DL9, is associated with resistance to HCV infection. A possible consequence of the absence of these receptors is that the C2 ligand is rendered less functional, and NK cell education becomes more targeted to the C1 epitope and its interactions with C1-specific Pt-KIR. In this circumstance the gene dose of the C1 epitope could become a critical factor and explain our observation that C1 + Patr-B homozygosity is detrimental for resolving HCV infection. Among the chimpanzees that resolved infection are ones with 0-3 copies of C1 but none with four copies. In contrast, two of the three chimpanzees, with chronic infection and who are C1 + Patr-B homozygous, encode four copies of the C1 epitope. NK cell education is sensitive to the abundance of the KIR ligand on the NK cell surface (Orr and Lanier 2010) , and the expression of MHC-B is considerably greater than that of MHC-C (Apps et al. 2015) . Thus, genotypes with two genes encoding C1 + Patr-B could reduce the effectiveness of C1-mediated NK cell education.
